Shasun buys worldwide rights for Scolr Pharma’s ibuprofen slow release tech
The 12-hour extended release of ibuprofen is a new technology and Shasun will commercialise this product after taking it through the final stages of development
Mumbai: Chennai-based drugs ingredients maker Shasun Pharmaceuticals Ltd has acquired the worldwide rights for a newly developed slow release technology of pain management drug ibuprofen and its brand title from US specialty drug researcher and manufacturer Scolr Pharma Inc. for an undisclosed sum.
The 12-hour extended release of ibuprofen, an old and established pain management drug, is a new technology and Shasun will commercialise this product after taking it through the final stages of development.
“The acquisition is the first among a series of strategic initiatives in our quest to continue to enhance our leadership in the non-steroid analgesic product segments," said Shasun managing director S. Abhaya Kumar on Monday.
Shasun also bought the brand name of Scolr’s ibuprofen formulation—Nuprin.
According to Shasun’s chief financial officer S. Hariharan, the slow release ibuprofen has an estimated market size of $50-60 million in the global market. The company will sell the product in the US first through the over-the-counter (OTC) channel and will launch the product in other markets, including India, through its OTC franchise.
Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!